Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors
Bodor J.N., Dowell J., Treat J., Subramanian J., Abdulla N., Lee E., Sankhala K., Lee C.-H., Makimoto G., Miyauchi E., Konduri K., Asahina H., Murakami S., Wen Y.-F., Luo Y.-H., Chang S.Y., Ewesuedo R., Zhou J., Goto Y.
May 28, 2025
Learn MoreCysteine specific targeting of the functionally distinct peroxiredoxin and glutaredoxin proteins by the investigational disulfide BNP7787(LP-300)
Parker A.R., Petluru P.N., Nienaber V.L., Badger J., Leverett B.D., Jair K., Sridhar V., Logan C., Ayala P.Y., Kochat H., Hausheer F.H.
March 18, 2015
Learn MoreNovel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787 (LP-300)
Parker A.R., Petluru P.N., Nienaber V.L., Zhao M., Ayala P.Y., Badger J., Chie-Leon B., Sridhar V., Logan C., Kochat H., Hausheer F.H.
February 4, 2015
Learn MorePhase I and pharmacologic study of BNP7787(LP-300), a novel chemoprotector in patients with advanced non-small cell lung cancer
Masuda N., Negoro S., Hausheer F., Nakagawa K., Matsui K., Kudoh S., Takeda K., Yamamoto N., Yoshimura N., Ohashi Y., Fukuoka M.
May 15, 2010
Learn MorePhase I and pharmacokinetic study of the novel chemoprotector BNP7787 (LP-300) in combination with cisplatin and attempt to eliminate the hydration schedule
Boven E., Westerman M., van Groeningen C.J., Verschraagen M., Ruijter R., Zegers I., van der Vijgh W.J.F., Giaccone G.
April 19, 2005
Learn More